Level B· Emerging clinical evidence with positive signalsClinical TrialPubMedOpen access

Mesenchymal Stem Cells: Therapeutic Mechanisms for Stroke.

Zhang Y., Dong N., Hong H., Qi J., Zhang S., Wang J.

Clinical Trial on Stroke Research, Neuroinflammation, Immune Modulation, published in Int J Mol Sci (2022) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Int J Mol Sci (2022)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
35269692
PMCID
PMC8910569
DOI
10.3390/ijms23052550
Citations
35

Abstract (original English)

Due to aging of the world's population, stroke has become increasingly prevalent, leading to a rise in socioeconomic burden. In the recent past, stroke research and treatment have become key scientific issues that need urgent solutions, with a sharp focus on stem cell transplantation, which is known to treat neurodegenerative diseases related to traumatic brain injuries, such as stroke. Indeed, stem cell therapy has brought hope to many stroke patients, both in animal and clinical trials. Mesenchymal stem cells (MSCs) are most commonly utilized in biological medical research, due to their pluripotency and universality. MSCs are often obtained from adipose tissue and bone marrow, and transplanted via intravenous injection. Therefore, this review will discuss the therapeutic mechanisms of MSCs and extracellular vehicles (EVs) secreted by MSCs for stroke, such as in attenuating inflammation through immunomodulation, releasing trophic factors to promote therapeutic effects, inducing angiogenesis, promoting neurogenesis, reducing the infarct volume, and replacing damaged cells.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsHumansMesenchymal Stem Cell TransplantationMesenchymal Stem CellsNeurodegenerative DiseasesNeurogenesisStroke

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research